Skip to main content

Skadden, Arps, Slate, Meagher & Flom and Fangda Partners have counselled Chinese Nasdaq-listed biotech company BeiGene on its $903 million dual primary listing in Hong Kong, with Davis Polk & Wardwell and JunHe advising the joint sponsors and underwriters.

The IPO, which is Hong Kong’s biggest biotech IPO till date, is also the first dual primary listing of a Nasdaq-listed biotech company.

The listing comes as Hong Kong works to lure overseas-listed firms to conduct secondary share offerings in the financial hub, said Reuters. Hong Kong’s stock exchange is seeking to establish itself as a financing centre for the growing number of pre-revenue drug developers.

BeiGene is a biopharmaceutical company focused on developing and commercialising molecularly targeted and immuno-oncology drugs for the treatment of cancer.

The Skadden team was headed by partners Christopher W. Betts and Andrea L. Nicolas, while partner Pamela Lawrence Endreny assisted on tax matters. Mourant Ozannes advised BeiGene on Caymans law.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com. 

Related Articles

Deals

Khaitan, JSA, Hogan Lovells guide $515 mln Waaree IPO

by Nimitt Dixit |

Khaitan & Co has advised Waaree Energies, India's largest manufacturer and exporter of solar modules, on its $515 million initial public offering, with JSA Advocates & Solicitors and Hogan Lovells guiding the bookrunning lead managers.

Deals

CAM, Khaitan guide Adani-backed Renew Exim’s $380 mln ITD acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Adani Group's Dubai-based firm Renew Exim DMCC on its acquisition of a 46.64 percent stake in ITD Cementation India for around $380 million from Italian-Thai Development Public Company, who was represented by Khaitan & Co.

Deals

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.